This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Otte A et al. (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24: 792–795
Eberle AN et al. (2004) Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors. J Recept Signal Transduct 24: 319–455
Jamar F et al. (2003) 86Y-DOTA-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30: 510–518
Paganelli G et al. (2002) 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66: 393–398
De Jong et al. (2005) Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 (Suppl 1): 13S–17S
Acknowledgements
The synopsis was written by Ian Newman, Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Eberle, A., Beglinger, C. Does 177Lu-labeled octreotate improve the rate of remission of endocrine gastroenteropancreatic tumors?. Nat Rev Endocrinol 1, 20–21 (2005). https://doi.org/10.1038/ncpendmet0028
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0028
